ClinicalTrials.gg
RecruitingNCT05414357ICANSLEEPUpdated Sep 30, 2026

Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer

An interventional study of Functional Magnetic Resonance Imaging at rest and in activation with attentional task in Breast Cancer, Sleep and Quality of Life, sponsored by Centre Francois Baclesse. Recruiting at 2 sites in France. Open to female participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Centre Francois Baclesse · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Updated Sep 30, 2026Eligibility revisedInterventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
45 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Breast Neoplasms by Centre Francois Baclesse — 4 open to participants now, 5 under way, none of them phase 3. Breast Neoplasms · Centre Francois Baclesse.

Planned enrollment
9th of 19
75 · median 75
Started
2023
the only one that year
No phase
12 of 23
3 open now
Registered
20th of 23
by date

Among the 23 studies in Breast Neoplasms by Centre Francois Baclesse, this one is the 9th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2023, is one of 12 with no phase, and was the 20th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 23 studies in Breast Neoplasms by Centre Francois Baclesse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 45 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Breast Neoplasms by Centre Francois Baclesse, or all of them as a file.
02

Study summary

Patients treated for breast cancer frequently complain of sleep disturbances, about 40% of them. Of the sleep disturbances experienced by patients, insomnia is the most common complaint. The prevalence of insomnia complaints is higher in breast cancer patients compared to other types of cancer, and is also higher than in the general population (between 20% and 70% in breast cancer patients vs 30% in the general population). A recent study indicates that sleep complaints concern 25% of patients even before diagnosis, and 46% (including 18% complaining of insomnia) at the time of diagnosis, showing the negative impact of the announcement of the pathology on the subjective quality of sleep, and particularly on symptoms suggestive of insomnia. However, objective information on a modification of sleep patterns in breast cancer remains scarce and does not allow us to conclude. In particular, previous studies have focused only on the effects of chemotherapy and have not always included a control group, limiting the significance of their results. The links with cognitive and psychopathological processes and the underlying mechanisms are not clearly demonstrated in this pathology. Finally, taking into account patients' complaints, it appears necessary to limit sleep disorders in breast cancer in order to improve patients' quality of life using non-medicinal and easy-to-implement approaches.

03

Conditions studied

  • Breast Cancer
  • Sleep
  • Quality of Life

Browse trials for

04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 39 to 69 years
  • A patient with localized breast cancer who has undergone surgery and may or may not be about to begin treatment with chemotherapy or radiation therapy
  • Patient with education level 3 "end of primary education"
  • Patient with a good command of the French language
  • Patient with access to the Internet from a computer at home
  • Patient having signed the consent to participate in the study
  • Patient with no pre-existing cognitive impairment at the time of cancer diagnosis
  • Patient with a sleep complaint (ISI > 7)

Exclusion criteria

Exclusion Criteria:

  • Patient with cancer
  • A patient with a primary cancer other than breast cancer and/or a history of treated cancer
  • Patient with a history of neurological damage
  • Patient with treated sleep apnea
  • Patient with drug use or alcohol abuse (≥3 drinks/day on average and/or >10 drinks/week)
  • Patient with a treatment that has not been stabilized for at least 3 months (hypnotics, antidepressants, anxiolytics)
  • Patient with a personality disorder and/or an evolving psychiatric pathology
  • Patient with a to MRI (claustrophobia, metallic objects in the body)
  • Patient with an uncorrected vision problem
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Patients with chemotherapy or radiotherapy

    Diagnostic Test: Functional Magnetic Resonance Imaging at rest and in activation with attentional task

  • Active comparator
    cancer-free volunteers

    Diagnostic Test: Functional Magnetic Resonance Imaging at rest and in activation with attentional task

Interventions

  • Diagnostic testFunctional Magnetic Resonance Imaging at rest and in activation with attentional task

    Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include: * Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2). * Biological and physiological measurements * Spatial memory task * Cognitive battery * Questionnaires (sleep, quality of life)

    Also known as: Spatial memory task, Cognitive battery, quality of life questionnaires

06

What researchers measure

Primary outcomes

  1. Ratio of total sleep time to time spent in bed and the number of awakenings lasting more than one minute measured by polysomnography with actimeter

    Time frame: At 6 months

  2. Amplitude of activity-rest rhythm measured with actimeter

    Time frame: At 6 months

  3. Acrophase of activity-rest rhythm measured with actimeter

    Time frame: At 6 months

07

Study locations

1 of 2 sites recruiting
  • Centre François Baclesse
    Caen, 14000, France
    Recruiting
    • Carine SEGURA-DJEZZAR, MD · Contactc.segura.djezzar@baclesse.unicancer.fr · +33 2 31 45 50 02
    • Carine SEGURA-DJEZZAR, MD · Principal investigator
    • Christelle LEVY, MD · Sub investigator
    • George EMILE, MD · Sub investigator
    • Adeline MOREL, MD · Sub investigator
  • Inserm-Ephe-Unicaen U1077
    Caen, 14000, France
    Not yet recruiting
    • Fausto VIADER, PhD · Contact
    • Fausto VIADER, PhD · Principal investigator
    • Vincent DE LA SAYETTE, PhD · Sub investigator
    • Olivier MARTINAUD, PhD · Sub investigator
    • Pierre DENISE, PhD · Sub investigator
08

References and documents

Publications

  • Galin M, de Girolamo L, Clarisse B, Segura-Djezzar C, Glockner F, Elia C, Rehel S, Clochon P, Doidy F, Chavant J, Etard O, Viader F, Grellard JM, Lequesne J, Joly F, Eustache F, Martin T, Giffard B, Quarck G, Perrier J. Exploration of effects of galvanic vestibular stimulation on circadian rhythms and its associations with sleep and spatial memory in patients with breast cancer: The ICANSLEEP-2 protocol. PLoS One. 2024 Jul 31;19(7):e0306462. doi: 10.1371/journal.pone.0306462. eCollection 2024. PubMed 39083526 ↗
  • Elia C, de Girolamo L, Clarisse B, Galin M, Rehel S, Clochon P, Doidy F, Segobin S, Viader F, Naveau M, Delcroix N, Segura-Djezzar C, Grellard JM, Lequesne J, Etard O, Martin T, Quarck G, Eustache F, Joly F, Giffard B, Perrier J. Effects of sleep disturbances and circadian rhythms modifications on cognition in breast cancer women before and after adjuvant chemotherapy: the ICANSLEEP-1 protocol. BMC Cancer. 2023 Dec 1;23(1):1178. doi: 10.1186/s12885-023-11664-x. PubMed 38041077 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2027, 48 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 48 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2022
First posted
Jun 10, 2022
StartActual
Mar 20, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPatientA patient with operated localized breast cancer who has undergone surgery and may or may not be startingabout to begin adjuvant treatment with chemotherapy or radiation therapy
Exclusion criteria
  • EditedPatientA patient with a primary cancer other than breast cancer and/or a history of treated cancer
Sep 30, 2026
Interventions
Arm changed Patients with chemotherapy→Patients with chemotherapy or radiotherapy. Arms removed: Patients without chemotherapy
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatientA patient with operated localized breast cancer who has undergone surgery and may or may not be startingabout to begin adjuvant treatment with chemotherapy or radiation therapy
    Exclusion criteria
    • EditedPatientA patient with a primary cancer other than breast cancer and/or a history of treated cancer
    Interventions Arm changed Patients with chemotherapy→Patients with chemotherapy or radiotherapy. Arms removed: Patients without chemotherapy
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05414357
Collaborators
UMR_S 1077 Inserm-EPHE-Normandie Université
Responsible party
Sponsor
First posted
Jun 10, 2022
Start date
Mar 20, 2023
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Carine SEGURA-DJEZZAR, MD
Contact
c.segura.djezzar@baclesse.unicancer.fr
+33 2 31 45 50 02

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion